Papers

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

^a Centre for Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, University of Newcastle, New South Wales, Australia, ^b Centro Espanol de Investigacion, Farmacoepidemiologica, Universidad Complutense de Madrid, 28040 Madrid, Spain, ^c Pharmacoepidemiology Research, Ciba-Geigy SA, Medical Department, 08013 Barcelona, Spain, ^d Division of General Internal Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA, ^e Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA, ^f Department of Rheumatology, Christchurch Hospital, Christchurch, New Zealand, ^g Department of Public Health and Epidemiology, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH, ^h Centre for Clinical Epidemiology and Community Studies, McGill University-Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada, ⁱ Division of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, ^j Therapeutics Goods Administration, Department of Human Services and Health, PO Box 100, Woden, ACT 2606, Australia, ^k Stanford University School of Medicine, Suite 203, Palo Alto, CA 94304-1808, USA

Abstract

Objective: To compare the relative risks of serious gastrointestinal complications reported with individual non-steroidal anti-inflammatory drugs.
Design: Systematic review of controlled epidemiological studies that found a relation between use of the drugs and admission to hospital for haemorrhage or perforation.
Setting: Hospital and community based casecontrol and cohort studies.
Main outcome measures: (a) Estimated relative risks of gastrointestinal complications with use of individual drugs, exposure to ibuprofen being used as reference; (b) a ranking that best summarised the sequence of relative risks observed in the studies.
Results: 12 studies met the inclusion criteria. 11 provided comparative data on ibuprofen and other drugs. Ibuprofen ranked lowest or equal lowest for risk in 10 of the 11 studies. Pooled relative risks calculated with exposure to ibuprofen used as reference were all significantly greater than 1.0 (interval of point estimates 1.6 to 9.2). Overall, ibuprofen was associated with the lowest relative risk, followed by diclofenac. Azapropazone, tolmetin, ketoprofen, and piroxicam ranked highest for risk and indomethacin, naproxen, sulindac, and aspirin occupied intermediate positions. Higher doses of ibuprofen were associated with relative risks similar to those with naproxen and indomethacin.
Conclusions: The low risk of serious gastrointestinal complications with ibuprofen seems to be attributable mainly to the low doses of the drug used in clinical practice. In higher doses ibuprofen is associated with a similar risk to other non-steroidal anti-inflammatory drugs. Use of low risk drugs in low dosage as first line treatment would substantially reduce the morbidity and mortality due to serious gastrointestinal toxicity from these drugs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial

Marlene Fransen, Craig Anderson, Jan Douglas, Stephen MacMahon, Bruce Neal, Robyn Norton, Mark Woodward, Ian D Cameron, Ross Crawford, Sing Kai Lo, Garnet Tregonning, Margaret Windolf HIPAID Collaborative Group
BMJ 2006 333: 519. [Abstract] [Full Text] [PDF]

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox, Carol Coupland, and Richard Logan
BMJ 2005 331: 1310-1316. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., Tang, J., Rosenstein, R. B., Umar, A., Bagheri, D., Collins, N. T., Burn, J., Chung, D. C., Dewar, T., Foley, T. R., Hoffman, N., Macrae, F., Pruitt, R. E., Saltzman, J. R., Salzberg, B., Sylwestrowicz, T., Hawk, E. T., for the Adenoma Prevention with Celecoxib Study In, (2009). Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research 2: 310-321 [Abstract] [Full text]  
• Haag, M. D. M., Bos, M. J., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., Stricker, B. H. C. (2008). Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke. Arch Intern Med 168: 1219-1224 [Abstract] [Full text]  
• Brune, K., Furst, D. E. (2007). Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?. Rheumatology (Oxford) 46: 911-919 [Abstract] [Full text]  
• Dube, C., Rostom, A., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D. (2007). The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED 146: 365-375 [Abstract] [Full text]  
• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full text]  
• Williams, J G, Roberts, S E, Ali, M F, Cheung, W Y, Cohen, D R, Demery, G, Edwards, A, Greer, M, Hellier, M D, Hutchings, H A, Ip, B, Longo, M F, Russell, I T, Snooks, H A, Williams, J C (2007). Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut 56: 1-113 [Full text]  
• Lanas, A, Garcia-Rodriguez, L A, Arroyo, M T, Gomollon, F, Feu, F, Gonzalez-Perez, A, Zapata, E, Bastida, G, Rodrigo, L, Santolaria, S, Guell, M, de Argila, C M, Quintero, E, Borda, F, Pique, J M, on behalf of the Investigators of the Asociacion E, (2006). Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55: 1731-1738 [Abstract] [Full text]  
• Huerta, C, Varas-Lorenzo, C, Castellsague, J, Garcia Rodriguez, L A (2006). Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 92: 1610-1615 [Abstract] [Full text]  
• Sutaria, S., Katbamna, R., Underwood, M. (2006). Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. Rheumatology (Oxford) 45: 1422-1431 [Abstract] [Full text]  
• Fransen, M., Anderson, C., Douglas, J., MacMahon, S., Neal, B., Norton, R., Woodward, M., Cameron, I. D, Crawford, R., Lo, S. K., Tregonning, G., Windolf, M., HIPAID Collaborative Group, (2006). Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 333: 519- [Abstract] [Full text]  
• Helin-Salmivaara, A., Virtanen, A., Vesalainen, R., Gronroos, J. M., Klaukka, T., Idanpaan-Heikkila, J. E., Huupponen, R. (2006). NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27: 1657-1663 [Abstract] [Full text]  
• Anderson, L. A., Johnston, B. T., Watson, R.G. P., Murphy, S. J., Ferguson, H. R., Comber, H., McGuigan, J., Reynolds, J. V., Murray, L. J. (2006). Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence.. Cancer Res. 66: 4975-4982 [Abstract] [Full text]  
• Elliott, R. A., Hooper, L., Payne, K., Brown, T. J., Roberts, C., Symmons, D. (2006). Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?. Rheumatology (Oxford) 45: 606-613 [Abstract] [Full text]  
• Hippisley-Cox, J., Coupland, C., Logan, R. (2005). Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-1316 [Abstract] [Full text]  
• Deyle, G. D, Allison, S. C, Matekel, R. L, Ryder, M. G, Stang, J. M, Gohdes, D. D, Hutton, J. P, Henderson, N. E, Garber, M. B (2005). Physical Therapy Treatment Effectiveness for Osteoarthritis of the Knee: A Randomized Comparison of Supervised Clinical Exercise and Manual Therapy Procedures Versus a Home Exercise Program. ptjournal 85: 1301-1317 [Abstract] [Full text]  
• Mollace, V., Muscoli, C., Masini, E., Cuzzocrea, S., Salvemini, D. (2005). Modulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide Donors. Pharmacol. Rev. 57: 217-252 [Abstract] [Full text]  
• Jobanputra, P., Arthur, V., Pugh, M., Spannuth, F., Griffiths, P., Thomas, E., Sheeran, T. (2005). Quality of care for NSAID users: development of an assessment tool. Rheumatology (Oxford) 44: 633-637 [Abstract] [Full text]  
• Dieppe, P., Bartlett, C., Davey, P., Doyal, L., Ebrahim, S. (2004). Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 329: 31-34 [Full text]  
• Richy, F, Bruyere, O, Ethgen, O, Rabenda, V, Bouvenot, G, Audran, M, Herrero-Beaumont, G, Moore, A, Eliakim, R, Haim, M, Reginster, J-Y (2004). Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759-766 [Abstract] [Full text]  
• Cox, E. R., Frisse, M., Behm, A., Fairman, K. A. (2004). Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users. Arch Intern Med 164: 1243-1246 [Full text]  
• Dickman, A., Ellershaw, J. (2004). For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?. Palliat Med 18: 275-286 [Abstract]  
• Hawkey, C J, Jones, J I, Atherton, C T, Skelly, M M, Bebb, J R, Fagerholm, U, Jonzon, B, Karlsson, P, Bjarnason, I T (2003). Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52: 1537-1542 [Abstract] [Full text]  
• Juni, P., Rutjes, A. W S, Dieppe, P. A (2003). The authors respond. BMJ 327: E141-142 [Full text]  
• Pavelka, K., Recker, D. P., Verburg, K. M. (2003). Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 42: 1207-1215 [Abstract] [Full text]  
• Russo, P., Capone, A., Attanasio, E., Baio, G., Di Martino, M., Degli Esposti, L., Marchetta, F., Buda, S., Degli Esposti, E., Caprino, L. (2003). Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice. Rheumatology (Oxford) 42: 879-887 [Abstract] [Full text]  
• Hawkey, C J, Langman, M J S (2003). Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52: 600-608 [Abstract] [Full text]  
• Reinacher-Schick, A., Schoeneck, A., Graeven, U., Schwarte-Waldhoff, I., Schmiegel, W. (2003). Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24: 443-451 [Abstract] [Full text]  
• Guignard, A. P, Couray-Targe, S., Colin, C., Chamba, G. (2003). Economic Impact of Pharmacists' Interventions with Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 37: 332-338 [Abstract] [Full text]  
• Bjornsson, G. A., Haanaes, H. R., Skoglund, L. A. (2003). Ketoprofen 75 mg qid versus Acetaminophen 1000 mg qid for 3 Days on Swelling, Pain, and Other Postoperative Events after Third-Molar Surgery. J Clin Pharmacol 43: 305-314 [Abstract] [Full text]  
• Warner, T. D., Mitchell, J. A. (2002). Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?. Proc. Natl. Acad. Sci. USA 99: 13371-13373 [Full text]  
• Mamdani, M., Rochon, P. A, Juurlink, D. N, Kopp, A., Anderson, G. M, Naglie, G., Austin, P. C, Laupacis, A. (2002). Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325: 624-624 [Abstract] [Full text]  
• Hawkey, C J, Naesdal, J, Wilson, I, Langstrom, G, Swannell, A J, Peacock, R A, Yeomans, N D (2002). Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 51: 336-343 [Abstract] [Full text]  
• Hawkey, C J, Wilson, I, Naesdal, J, Langstrom, G, Swannell, A J, Yeomans, N D (2002). Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 51: 344-350 [Abstract] [Full text]  
• Lai, K. C., Lam, S. K., Chu, K. M., Wong, B. C.Y., Hui, W. M., Hu, W. H.C., Lau, G. K.K., Wong, W. M., Yuen, M. F., Chan, A. O.O., Lai, C. L., Wong, J. (2002). Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use. NEJM 346: 2033-2038 [Abstract] [Full text]  
• Perkins, S., Verschoyle, R. D., Hill, K., Parveen, I., Threadgill, M. D., Sharma, R. A., Williams, M. L., Steward, W. P., Gescher, A. J. (2002). Chemopreventive Efficacy and Pharmacokinetics of Curcumin in the Min/+ Mouse, a Model of Familial Adenomatous Polyposis. Cancer Epidemiol. Biomarkers Prev. 11: 535-540 [Abstract] [Full text]  
• Hawkey, C J (2002). Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut 50: iii25-30 [Abstract] [Full text]  
• Seager, J M, Hawkey, C J (2001). ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs. BMJ 323: 1236-1239 [Full text]  
• HALTER, F, TARNAWSKI, A S, SCHMASSMANN, A, PESKAR, B M (2001). Cyclooxygenase 2{---}implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49: 443-453 [Abstract] [Full text]  
• Ince, A. (2001). Guest Editorial: The Use of COX-2-Specific Inhibitors: Is It All Hype or Is It Evidence Based?. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56: 136M-137 [Full text]  
• Tramèr, M. R (2000). Aspirin, like all other drugs, is a poison. BMJ 321: 1170-1171 [Full text]  
• Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., Geis, G. S. (2000). Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. JAMA 284: 1247-1255 [Abstract] [Full text]  
• Hernandez-Diaz, S., Rodriguez, L. A. G. (2000). Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation: An Overview of Epidemiologic Studies Published in the 1990s. Arch Intern Med 160: 2093-2099 [Abstract] [Full text]  
• van Haselen, R. A., Fisher, P. A. G. (2000). A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford) 39: 714-719 [Abstract] [Full text]  
• Moynihan, R., Bero, L., Ross-Degnan, D., Henry, D., Lee, K., Watkins, J., Mah, C., Soumerai, S. B. (2000). Coverage by the News Media of the Benefits and Risks of Medications. NEJM 342: 1645-1650 [Abstract] [Full text]  
• Gøtzsche, P. C (2000). Extracts from "Clinical Evidence": Non-steroidal anti-inflammatory drugs. BMJ 320: 1058-1061 [Full text]  
• Chow, H-H. S., Earnest, D. L., Clark, D., Mason-Liddil, N., Kramer, C. B., Einspahr, J. G., Guillen-Rodriguez, J. M., Roe, D. J., Malone, W., Crowell, J. A., Alberts, D. S. (2000). Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps. Cancer Epidemiol. Biomarkers Prev. 9: 351-356 [Abstract] [Full text]  
• Llop, C, Paredes, S, Llor, C (2000). Criteria for selecting and using non-steroidal anti-inflammatory drugs in primary health care. Fam Pract 17: 63-65 [Abstract] [Full text]  
• Po, A. L. W. (1999). Antidepressants and upper gastrointestinal bleeding. BMJ 319: 1081-1082 [Full text]  
• Panara, M. R., Renda, G., Sciulli, M. G., Santini, G., Di Giamberardino, M., Rotondo, M. T., Tacconelli, S., Seta, F., Patrono, C., Patrignani, P. (1999). Dose-Dependent Inhibition of Platelet Cyclooxygenase-1 and Monocyte Cyclooxygenase-2 by Meloxicam in Healthy Subjects. J. Pharmacol. Exp. Ther. 290: 276-280 [Abstract] [Full text]  
• Scharf, S., Mander, A., Ugoni, A., Vajda, F., Christophidis, N. (1999). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53: 197-197 [Abstract] [Full text]  
• Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., Vane, J. R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 96: 7563-7568 [Abstract] [Full text]  
• Ritland, S. R., Gendler, S. J. (1999). Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 20: 51-58 [Abstract] [Full text]  
• Sigthorsson, G, Tibble, J, Hayllar, J, Menzies, I, Macpherson, A, Moots, R, Scott, D, Gumpel, M J, Bjarnason, I (1998). Intestinal permeability and inflammation in patients on NSAIDs. Gut 43: 506-511 [Abstract] [Full text]  
• Eccles, M., Freemantle, N., Mason, J. (1998). North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 317: 526-530 [Full text]  
• (1998). {blacktriangledown}Meloxicam-a safer NSAID?. DTB 36: 62-64 [Abstract] [Full text]  
• Brooks, P. (1998). Recent advances: Rheumatology. BMJ 316: 1810-1812 [Full text]  
• Hawkey, C. J., Karrasch, J. A., Szczepanski, L., Walker, D. G., Barkun, A., Swannell, A. J., Yeomans, N. D., The Omeprazole versus Misoprostol for NSAID-Induce, (1998). Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. NEJM 338: 727-734 [Abstract] [Full text]  
• Garcia Rodriguez, L. A., Cattaruzzi, C., Troncon, M. G., Agostinis, L. (1998). Risk of Hospitalization for Upper Gastrointestinal Tract Bleeding Associated With Ketorolac, Other Nonsteroidal Anti-inflammatory Drugs, Calcium Antagonists, and Other Antihypertensive Drugs. Arch Intern Med 158: 33-39 [Abstract] [Full text]  
• Strom, B. L., Schinnar, R., Bilker, W. B., Feldman, H., Farrar, J. T., Carson, J. L. (1997). Gastrointestinal Tract Bleeding Associated With Naproxen Sodium vs Ibuprofen. Arch Intern Med 157: 2626-2631 [Abstract]  
• Pahor, M., Applegate, W. B (1997). Recent advances: Geriatric medicine. BMJ 315: 1071-1074 [Full text]  
• Miwa, L. J., Jones, J. K., Pathiyal, A., Hatoum, H. (1997). Value of Epidemiologic Studies in Determining the True Incidence of Adverse Events: The Nonsteroidal Anti-inflammatory Drug Story. Arch Intern Med 157: 2129-2136 [Abstract]  
• Henry, D. (1997). Systematic reviews provide information not contained in traditional narrative reviews. BMJ 314: 1832-1832 [Full text]  
• (1996). WHEN IT COMES TO GI SIDE-EFFECTS, NOT ALL NSAIDS ARE ALIKE. JWatch General 1996: 4-4 [Full text]